Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $13.3 million.

  • Intellia Therapeutics' Accounts Payables rose 87.49% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 million, marking a year-over-year increase of 87.49%. This contributed to the annual value of $14.6 million for FY2024, which is 9577.29% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Accounts Payables of $13.3 million as of Q3 2025, which was up 87.49% from $9.8 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Accounts Payables peaked at $18.8 million during Q2 2024, and registered a low of $3.6 million during Q3 2023.
  • For the 5-year period, Intellia Therapeutics' Accounts Payables averaged around $9.7 million, with its median value being $9.7 million (2021).
  • Per our database at Business Quant, Intellia Therapeutics' Accounts Payables soared by 9781428.57% in 2021 and then plummeted by 4790.6% in 2025.
  • Intellia Therapeutics' Accounts Payables (Quarter) stood at $9.7 million in 2021, then tumbled by 46.61% to $5.2 million in 2022, then skyrocketed by 44.59% to $7.5 million in 2023, then soared by 95.77% to $14.6 million in 2024, then decreased by 9.11% to $13.3 million in 2025.
  • Its Accounts Payables was $13.3 million in Q3 2025, compared to $9.8 million in Q2 2025 and $12.4 million in Q1 2025.